Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Status:
Recruiting
Trial end date:
2025-03-13
Target enrollment:
Participant gender:
Summary
This is a single-arm, unicentric, single-stage clinical study of tamoxifen for patients with
well differentiated neuroendocrine tumors and radiological progression with positive (> 1
percent) HR (estrogen and / or progesterone) expression by IHC. It will evaluate if Tamoxifen
exerts antitumor action in patients with well differentiated NET and positive for the
expression of HR, estrogen and / or progesterone.